Alterity Therapeutics Ltd (ATH)

Snapshot

ATH's Principal Activity is the commercialise research into Parkinsonian movement disorders, Alzheimer's disease, Huntington disease and other neurodegenerative disorders.

Announcements

Corporate Overview

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date	Amount	Franking	Gross	Type	Payable
No dividends paid.

Show All

See Upcoming Dividends for all ASX companies.

Directors & Management

Name	Title	Since	Bio
Dr David Stamler	Chief Executive Officer	Jan 2021
Mr David Sinclair	Non-Executive Director	Apr 2019	Mr David Sinclair Non-Executive Director Dr Sinclair is the co-founder and chairman of Life Biosciences LLC. He is also a tenured professor in the Department of Genetics at Harvard Medical School, a co-director of the Paul F. Glenn Center for the Biology of Aging Research, and serves on the non-profit boards of the American Federation for Aging Research and the Sanford Lorraine Cross Award. He has co-founded biotechnology and genomics companies which work on aging, neurological, metabolic, infectious and rare diseases.
Mr Tristan Edwards	Non-Executive Director	Apr 2019	Mr Tristan Edwards Non-Executive Director Mr Edwards is the co-founder and President of Life Biosciences LLC. He has financial capital markets, regulatory compliance, and fiduciary oversight experience, following a 16 year investment career spanning financial organizations across Australia, London, HK and Singapore. His background has been in senior investment roles at financial groups such as Goldman Sachs, Brevan Howard, Trafalgar Capital and Mosaic Asset Management. He started his career as an analyst with the Australian Commonwealth Department of Finance.
Mr Phillip Hains	Company Secretary	May 2014
Mr Lawrence Gozlan	Non-Executive Director	Aug 2011	Mr Lawrence Gozlan Non-Executive Director Mr Gozlan is the Chief Investment Officer and Founder of Scientia Capital, a investment fund which has focus in life sciences. Prior to this, Mr Gozlan was in charge for the biotechnology investment portfolio in Australia as the institutional biotechnology analyst at QIC ("the Queensland Investment Corporation"). He previously worked as the senior biotechnology analyst in the equities team at Foster Stockbroking Pty Ltd, and gained senior corporate finance experience advising life sciences companies at Deloitte. Mr Gozlan is currently direcor of number of private biotechnology companies in the USA.
Mr Peter Ashley Marks	Non-Executive Director	Jul 2005	Mr Peter Ashley Marks Non-Executive Director Mr Marks for over 13 years until the end of August 2014 was a Director of Peregrine Corporate Ltd, an Australian-based investment banking and corporate advisory firm. Mr Marks was until 2016, a Director of Armadale Capital Plc, which has focus on natural resources projects based in Africa with its current investments being a gold exploration company in DRC and a coal briquetting operation in South Africa. Mr Marks is currently a Consultant at Henslow Pty Ltd, a corporate and capital markets advisory firm. Mr. Marks is also a nonexecutive director of Terragenic International Ltd, an unlisted public company and has develop a novel hydrogen fuel system. From September 1998 until March 2001, Mr Marks was working with KPMG Corporate Finance Ltd (Australia), where he rose to Director and was in charge for heading up the equity capital markets group in Melbourne. From January 1992 until July 1994, Mr. Marks served as Head of the Melbourne Companies Department at the ASX and was founding Director of Momentum Funds Management Pty Ltd, an Australian venture capital firm. From December 1990 until December 1991, Mr Marks served as Director of Corporate Finance at Burdett Buckeridge & Young Ltd in their Melbourne offices, from August 1988 until November 1990, he held senior corporate finance position at Barings Securities Ltd, and from July 1985 until July 1988, he served as an Associate Director of McIntosh Securities, now Merrill Lynch Australia. In his roles with these financial institutions, Mr Marks was in charge for advising a number of listed and unlisted companies on issues ranging from corporate and company structure, to valuation, business strategies, acquisitions and international opportunities.
Mr Geoffrey Paul Kempler	Non-Executive Chairman,Non-Executive Director	Jun 2005	Mr Geoffrey Paul Kempler Non-Executive Chairman,Non-Executive Director Mr Kempler has served as our Chief Executive Officer, and in June 2005 he again assumed the position of Chief Executive Officer. Mr Kempler has experience in investment and business development, has been in charge for the implementation of our strategic plan and the commercialisation of our technology.
Mr Brian Derek Meltzer	Non-Executive Director	Dec 1999	Mr Brian Derek Meltzer Non-Executive Director Mr Meltzer spent 25 years in investment banking. His breadth of expertise includes property transactions, corporate advisory, corporate finance, management buyouts, venture capital and syndications. He has held a number of Board and Board Advisory roles for private companies in the human resources, health, aged care, software, entertainment and finance sectors, including Director of a federal government Innovation Investment Fund. Mr Meltzer is also a Director of the Australia-Israel Chamber of Commerce, Chairman of Independence Australia and Chairman of a privately owned corporate health and wellness business.
David Stamler	Chief Executive Officer	N/A

Show All

Director Transactions

Date	Director	Type	Amount	Price	Value	Notes
18/09/20	Tristan Edwards	Issued	7,000,000	$0.054	$378,000	Issue of options
18/09/20	Peter Marks	Issued	7,000,000	$0.054	$378,000	Issue of options
18/09/20	Lawrence Gozlan	Issued	7,000,000	$0.054	$378,000	Issue of options
18/09/20	Geoffrey Kempler	Issued	14,000,000	$0.054	$756,000	Issue of options
18/09/20	David Sinclair	Issued	7,000,000	$0.054	$378,000	Issue of options
18/09/20	Brian Meltzer	Issued	7,000,000	$0.054	$378,000	Issue of options

Show All

Director Interests

Director	Last Notice	Direct Shares	Indirect Shares	Options	Convertibles
Tristan Edwards	30/06/2021	N/A	N/A	7,000,000	N/A
Lawrence Gozlan	30/06/2021	N/A	N/A	8,250,000	N/A
Peter Marks	30/06/2021	43,111	N/A	8,250,000	N/A
Brian Meltzer	30/06/2021	326,666	N/A	8,250,000	N/A
Geoffrey Kempler	30/06/2021	30,000	17,981,000	19,000,000	N/A
David Sinclair	30/06/2021	N/A	N/A	7,000,000	N/A

Show All

Top 20 Shareholders

About the Data

Name	Shares	Capital
HSBC Custody Nominees (Australia) Limited	1,358,556,242	56.44%
Life Biosciences Llc	269,905,533	11.21%
Jagen Pty Ltd	38,556,497	1.60%
1215 Capital Pty Ltd	18,733,028	0.78%
Rentuk Shore Pty Ltd	15,641,719	0.65%
Capuano Nominees Pty Ltd (The Hartman Investment A/C)	15,000,000	0.62%
Andrew Mark Wilmot Seton	14,795,663	0.61%
Citicorp Nominees Pty Limited	14,394,030	0.60%
Baywick Proprietary Limited (The Retail Discretionary A/C)	14,165,000	0.59%
BNP Paribas Nominees Pty Ltd Acf Clearstream	12,164,297	0.51%
Fagan Harris Pty Ltd (Fagan Harris Super Fund A/C)	9,500,000	0.39%
Mr Benjamin Woolvett	7,210,000	0.30%
Mr Bill Konstad & Mrs Despina Konstad (The B&D Konstad S F Ac)	6,195,856	0.26%
Mr David John Southon (Southon Family A/C)	6,000,000	0.25%
Mr Minh Huy Lam	6,000,000	0.25%
Mr Huy Nguyen (Huy Nguyen Super Fund A/C)	5,380,195	0.22%
Mr Anurag Pandey	5,020,000	0.21%
Citos Super Pty Ltd (Citos Pty Ltd Sf A/C)	5,000,000	0.21%
Mr Christopher Robert Schroeter	4,778,958	0.20%
Donatello Nizzi	4,678,362	0.19%

Show All

Shareholder Distribution

As reported in the most recent Annual Report.

Substantial Shareholders

Shareholders Buying

12 month transaction history compiled from ASX announcements.

Shareholders Selling

12 month transaction history compiled from ASX announcements.

Share Price History

Date	Close	Change	%Chg	Open	High	Low	Volume	Turnover

Full Month

Historical Data

Year	Closing Price	Last Trade
2020	$0.017	30 June
2019	$0.029	28 June

ATH Historical Price Data (CSV)

Up to 20 years of EOD share price history

Sign up to Download

You must be logged in to access this feature. Please sign up for free or login.